Linden HM, O'Brien SR, van de Ven SM, La Porte P, et al. Clinical Utility of [(18)F]Fluoroestradiol PET/CT to Guide Second Line Treatment Decision in ER-Positive HER2-Negative Metastatic Breast Cancer After Progression on First Line Endocrine Therapy. Clin Breast Cancer 2026;26:32-39.
PMID: 42892305